Is bdrx a good buy

**Biodexa Pharmaceuticals (BDRX) is not a good buy at this time.** Here's why:

1. **Financial Performance**: The company has reported a net income of $0.00 million and a diluted EPS of $0.00 for the most recent quarter, indicating a loss in earnings. This is a concern as it shows that the company is not generating profits.

2. **Revenue Growth Rate**: The company's revenue growth rate is negative at -30.85%, which could be indicative of underlying issues with the company's business model or market position.

3. **Stock Compliance Issues**: The company has been notified by Nasdaq of its intention to delist due to a closing bid price below $1 for 30 consecutive business days. This could impact investor confidence and the company's ability to raise capital.
4. **Strategic Adjustments**: The company has announced a change in the ratio of its American Depositary Receipts, which could be seen as a strategic attempt to comply with Nasdaq's minimum bid price requirement. However, the company has stated that it cannot assure that this change will achieve compliance.

In conclusion, the financial losses, negative revenue growth rate, and stock compliance issues suggest that BDRX is not in a strong position to make a significant investment. Investors should carefully consider these factors and monitor the company's future performance before making an investment decision.